A5058008687- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Complement system in diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- Quinazolinone synthesis and applications
- Renal Diseases and Glomerulopathies
- Hemoglobinopathies and Related Disorders
- Blood groups and transfusion
- Platelet Disorders and Treatments
- Renal Transplantation Outcomes and Treatments
- Hematopoietic Stem Cell Transplantation
- Pharmacological Effects and Toxicity Studies
- Infectious Diseases and Mycology
- Immune Cell Function and Interaction
- Retinoids in leukemia and cellular processes
- CNS Lymphoma Diagnosis and Treatment
- Parathyroid Disorders and Treatments
- Hematological disorders and diagnostics
- Antifungal resistance and susceptibility
- Amyloidosis: Diagnosis, Treatment, Outcomes
Marmara University
2019-2025
Izmir Atatürk Eğitim ve Araştırma Hastanesi
2016-2020
Palmetto Hematology Oncology
2019
Ege University
2013-2017
Izmir Kâtip Çelebi University
2016-2017
Glofitamab is a CD3xCD20 bi-specific antibody with two fragments directed to the CD20 antigen and single CD3-binding fragment. Encouraging response survival rates were recently reported in pivotal phase II expansion trial conducted patients relapsed/refractory (R/R) B-cell lymphoma. However, real-world data of all ages no strict selection criteria are still lacking. Herein, this retrospective study aimed evaluate outcomes diffuse large lymphoma (DLBCL) who received glofitamab via...
Background While there has been no direct head-to-head comparison, it is assumed that second-line treatment with dasatinib and nilotinib comparable efficacy but distinct safety profiles in the of patients chronic phase myeloid leukemia (CML-CP). Our aim was to conduct a real-world analysis compare these two agents.
Intravascular large B-cell lymphoma (IVLBCL) is a very rare type of non-Hodgkin lymphoma, usually affecting elderly patients and characterized by selective infiltration neoplastic cells within blood vessels' lumina. IVLBCL diagnosed with prostatic involvement extremely rare. We report patient 65 years old, having mostly neurological complaints but upon histopathological examination transurethral prostate resection material, which revealed cell totally limited the lumens small vessels. By...
Hereditary hyperferritinemia-cataract syndrome (HHCS) is a rare genetic condition characterized by persistent hyperferritinemia (usually ferritin >1,000 ng/mL) without tissue iron overload, with or early-onset slow-progressing bilateral nuclear cataract. It was first identified as new disorder in 1995, and since then sequencing studies have been carried out to identify associated mutations affected families. New around the world are still being reported iron-responsive element (IRE) of...
The aim of the study was to examine relation between additional chromosomal aberrations (ACAs) with major molecular response (MMR) and BCR-ABL kinase domain (KD) mutations in long-term follow-up chronic myeloid leukemia (CML) disease. design cross-sectional observational used CML patients’ data Izmir Ataturk Education Research Hospital from 2011 2015. Conventional cytogenetic, fluorescence situ hybridization (FISH), quantitative real-time polymerase chain reaction (RQ-PCR) test results 89...
Objective: Acute leukemia often involves comorbidities, impacting treatment decisions and patient outcomes. Clinicians commonly use the Charlson Comorbidity Index (CCI) Hematopoietic Stem Cell Transplantation (HCT-CI) to assess their influence. However, effectiveness in predicting survival non-relapse mortality (NRM) acute patients under 65 undergoing allogeneic stem cell transplantation remains unclear. Patients Methods: We conducted a retrospective single-center analysis on adults...
Diffuse large B-cell primary gastric lymphomas (DLBC-PGLs) are treated with different therapies. Their optimal treatment is not well documented.We retrospectively analyzed the data of 51 patients diagnosed DLBC-PGL in previous 10 years. All were R-CHOP as first line. Radiotherapy was added to chemotherapy 8 patients. Surgery performed 5 patients.The median follow-up time 45.5 (range 5-144) months and complete response (CR) rate 90.2%. CR achieved 34 (89.4%) 38 single chemotherapy, all (100%)...
Myeloid or granulocytic sarcoma (GS) is a tumoral lesion consisting of immature cells. It rare entity during the course CML patients especially after allogeneic stem cell transplantation (SCT). Relapse without bone marrow involvement much rarer. We report case patient who relapsed with isolated SCT cytogenetic and molecular remission. 28-year-old male was diagnosed as performed because refractory disease to tyrosine kinase inhibitors. Complete response achieved followed by dasatinib...
Sarcoidosis is a chronic granulomatous disease of unknown etiology characterized by non-caseified granulomas in many different organs and systems. The most frequently manifests with bilateral hilar lymphadenopathy infiltrations the lungs skin, as well eye lesions. It may mimic number systemic diseases and/or accompany them. development lymphoma patients sarcoidosis or co-occurrence both rarely reported literature. In this paper we report female patient followed up for three years who...